Portal de Periódicos da CAPES

Relación costo-efectividad de las intervenciones preventivas contra el cáncer cervical en mujeres mexicanas

2008; Instituto Nacional de Salud Pública; Volume: 50; Issue: 2 Linguagem: Inglês

10.1590/s0036-36342008000200004

1606-7916

Cristina Gutiérrez-Delgado, Camilo Báez-Mendoza, Eduardo González-Pier, Alejandra Prieto de la Rosa, Renee Witlen,

Global Cancer Incidence and Screening

To develop a generalized cost-effectiveness analysis (GCEA) of the HPV vaccine, hybrid capture screening (HC) and Papanicolaou screening (Pap) in the Mexican context.From April to August 2007, in Mexico, a GCEA of the interventions was developed for 10 possible scenarios using a Markov model from the public sector perspective as payer.Scenarios considering 80% coverage show an ACER per DALY averted of $16678 pesos for Pap of women between ages 25 and 64, $17277 pesos for HC of women between ages 30 and 64, and $84008 pesos for vaccination of 12-year-old girls. Annual financing of $621, $741 and $2255 million pesos, respectively, is needed for these scenarios.A selective, combined introduction of Pap-HC screening that considers the comparative advantages of application in different populations and geographical areas is suggested. Additionally, it is suggested to introduce the vaccine once a threshold price of $181 pesos per dose -when the vaccine becomes equal in terms of cost-effectiveness to HC- has been achieved.